Abstract: [PROBLEM TO BE SOLVED] To provide a method for producing ether phospholipids of high purity by an easy process. [SOLUTION] This production method comprises: (A) a step of extracting total lipids from organisms with non-polar organic solvent and branched alcohol mixture; and (B) a step of reacting the total lipids obtained by the step (A) with phospholipase A1 to decompose mixed diacyl-glycerophospholipids. This makes it possible to produce plasmalogen-type glycerophospholipids or ether phospholipids of high purity by an easy process.

Abstract: Provided is a novel hair growth and hair restoration material having excellent efficacy in hair growth and hair restoration for both men and women, even when the components thereof are at ultra-dilute concentrations; the hair growth and hair restoration material being characterized in containing a sterol glucopyranoside, preferably a cholesteryl glucopyranoside, represented by general formula (I). (In the formula, Z represents a sterol residue from which the hydroxyl group attached to the 3-position of a cyclopentanohydrophenanthrene ring has been removed.

Abstract: Provided is a novel hair growth and hair restoration material having excellent efficacy in hair growth and hair restoration for both men and women, even when the components thereof are at ultra-dilute concentrations; the hair growth and hair restoration material being characterized in containing a steryl glucopyranoside, preferably a cholesteryl glucopyranoside, represented by general formula (I). (In the formula, Z represents a sterol residue from which the hydroxyl group attached to the 3-position of a cyclopentanohydrophenanthrene ring has been removed.

Abstract: An objective of the present invention is to provide a new substance having a cerebral nerve cell neogenesis effect. Another objective is to provide a cerebral nerve cell neogenesis agent that is effective in treating and/or preventing neurological disorders utilizing the substance. With the present invention, a cerebral nerve cell neogenesis agent containing a plasmalogen as an active ingredient is provided. In particular, a preferable cerebral nerve cell neogenesis agent contains, as an active ingredient, a biological tissue (preferably, an avian tissue) extracted plasmalogen mainly including an ethanolamine plasmalogen and a choline plasmalogen.

Abstract: An objective of the present invention is to provide a novel method with an effect of alleviating central nervous system inflammation. The present invention provides a drug against central nervous system inflammation containing a plasmalogen. More preferably, the present invention provides a drug against central nervous system inflammation containing a plasmalogen extracted from a biological tissue (preferably an avian tissue) that mainly contains an ethanolamine plasmalogen and a choline plasmalogen.

Abstract: An objective of the present invention is to provide a new substance having a cerebral nerve cell neogenesis effect. Another objective is to provide a cerebral nerve cell neogenesis agent that is effective in treating and/or preventing neurological disorders utilizing the substance. With the present invention, a cerebral nerve cell neogenesis agent containing a plasmalogen as an active ingredient is provided. In particular, a preferable cerebral nerve cell neogenesis agent contains, as an active ingredient, a biological tissue (preferably, an avian tissue) extracted plasmalogen mainly including an ethanolamine plasmalogen and a choline plasmalogen.

Abstract: Disclosed is a process for producing sphingomyelin and plasmalogen-form glycerophospholipid, which comprises the step (A) of extracting a total lipids from a chicken skin powder and drying the extract, the step (B) of subjecting the dried total lipids obtained in said step (A), to extraction treatment with a solvent mixture of an aliphatic hydrocarbon solvent and a water-soluble ketone solvent to separate an insoluble portion composed mainly of sphingomyelin and a soluble portion, the step (C) subjecting the insoluble portion composed mainly of sphingomyelin, obtained in said step (B), to extraction treatment with a solvent mixture of water and a water-soluble ketone solvent to remove a non-lipid component contained in the soluble portion, and the step (D) of drying the soluble portion obtained in said step (B), and subjecting the thus-obtained dried product to extraction treatment with a water-soluble ketone solvent to separate and recover an insoluble portion composed mainly of plasmalogen-form giycerophosp

Abstract: A process for preparing a functional material by heat-treating a skin portion of poultry to carry out deoiling and defatting and to concentrate and pasteurize human-type sphingomyelin and plasmalogen-type glycerophospholipid contained in said skin portion, said heat-treatment comprising the steps of (A) continuously injecting hot water heated to 100° C. or higher and/or steam into a heating chamber of a semi-sealed space having said temperature or higher, to generate water microdroplets and moist hot steam, (B) replacing air in said heating chamber with said water microdroplets and moist hot steam, to fill a gas component (gaseous water) that has a composition having a relative humidity of 95% or more and an oxygen concentration of 0.2% by volume or less and that is maintained in a temperature range of 100 to 115° C.

Abstract: Disclosed is a process for producing sphingomyelin and plasmalogen-form glycerophospholipid, which comprises the step (A) of extracting a total lipids from a chicken skin powder and drying the extract, the step (B) of subjecting the dried total lipids obtained in said step (A), to extraction treatment with a solvent mixture of an aliphatic hydrocarbon solvent and a water-soluble ketone solvent to separate an insoluble portion composed mainly of sphingomyelin and a soluble portion, the step (C) subjecting the insoluble portion composed mainly of sphingomyelin, obtained in said step (B), to extraction treatment with a solvent mixture of water and a water-soluble ketone solvent to remove a non-lipid component contained in the soluble portion, and the step (D) of drying the soluble portion obtained in said step (B), and subjecting the thus-obtained dried product to extraction treatment with a water-soluble ketone solvent to separate and recover an insoluble portion composed mainly of plasmalogen-form giycerophosp